Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.

about

New Strategies Using Antibody Combinations to Increase Cancer Treatment Effectiveness.

P2860

Q47221234-6511B264-6D01-4229-96B6-5145E844B2D8

P2860

Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.

Item

http://www.wikidata.org/entity/Q38640845

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年論文

@yue

2017年論文

@zh-hant

2017年論文

@zh-hk

2017年論文

@zh-mo

2017年論文

@zh-tw

2017年论文

@wuu

2017年论文

@zh

2017年论文

@zh-cn

name

Pembrolizumab in the treatment ...... a review of current evidence.

@en

type

Item

label

Pembrolizumab in the treatment ...... a review of current evidence.

@en

prefLabel

Pembrolizumab in the treatment ...... a review of current evidence.

@en

P1476

Pembrolizumab in the treatment ...... a review of current evidence.

@en

P2093

Andrea Ardizzoni

http://www.w3.org/2001/XMLSchema#string

Barbara Melotti

http://www.w3.org/2001/XMLSchema#string

Francesca Sperandi

http://www.w3.org/2001/XMLSchema#string

Karim Rihawi

http://www.w3.org/2001/XMLSchema#string

Laura Casolari

http://www.w3.org/2001/XMLSchema#string

Michelangelo Fiorentino

http://www.w3.org/2001/XMLSchema#string

P2860

Mutational heterogeneity in cancer and the search for new cancer-associated genes

Safety, activity, and immune correlates of anti-PD-1 antibody in cancer

Predictive factors of activity of anti-programmed death-1/programmed death ligand-1 drugs: immunohistochemistry analysis

Advances in immunotherapy for treatment of lung cancer

Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial.

Crizotinib versus chemotherapy in advanced ALK-positive lung cancer.

Ceritinib in ALK-rearranged non-small-cell lung cancer.

Differential Activity of Nivolumab, Pembrolizumab and MPDL3280A according to the Tumor Expression of Programmed Death-Ligand-1 (PD-L1): Sensitivity Analysis of Trials in Melanoma, Lung and Genitourinary Cancers.

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial.

Cancer statistics, 2015

P304

353-373

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.1177/1753465817725486

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Francesco Gelsomino

P577

2017-08-17T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

28818019

http://www.w3.org/2001/XMLSchema#string

P932

5933587

http://www.w3.org/2001/XMLSchema#string

Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.

about

P2860

P2860

Pembrolizumab in the treatment of metastatic non-small cell lung cancer: a review of current evidence.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P932